id,name,unit,description,createdAt,updatedAt,code,coverage,timespan,datasetId,sourceId,shortUnit,display,columnOrder,originalMetadata,grapherConfigAdmin,shortName,catalogPath,dimensions,schemaVersion,processingLevel,processingLog,titlePublic,titleVariant,attributionShort,attribution,descriptionShort,descriptionFromProducer,descriptionKey,descriptionProcessing,licenses,license,grapherConfigETL,type,sort,dataChecksum,metadataChecksum
815287,Statin use for primary prevention amongst elibible individuals,%,,2023-10-10 15:55:36,2024-07-08 17:24:04,,,2019-2019,6266,,%,"{""unit"": ""%"", ""shortUnit"": ""%"", ""numDecimalPlaces"": 1}",0,,,statin_use_primary,grapher/statins/2023-10-05/lancet_2022/lancet_2022#statin_use_primary,,2,minor,,,,,,Proportion of eligible individuals self-reporting use of statins for the primary prevention of cardiovascular disease,Eligibility for statin therapy for primary prevention was defined among individuals with a history of diagnosed diabetes or a 10-year cardiovascular disease risk of at least 20%.,[],,,,,float,[],ecfd6018675aa95b66e8dfc2018895ca,fbdcd19cb67676858d4f95e45d5cc2f0
815286,Statin use for secondary prevention amongst elibible individuals,%,,2023-10-10 15:55:35,2024-07-08 17:24:04,,,2019-2019,6266,,%,"{""unit"": ""%"", ""shortUnit"": ""%"", ""numDecimalPlaces"": 1}",0,,,statin_use_secondary,grapher/statins/2023-10-05/lancet_2022/lancet_2022#statin_use_secondary,,2,minor,,,,,,Proportion of eligible individuals self-reporting use of statins for the secondary prevention of cardiovascular disease,Eligibility for statin therapy for secondary prevention was defined among individuals with a history of self-reported cardiovascular disease.,[],,,,,float,[],ded684a717cb9dd22217ad0c692b52fa,d13901ec727f3955d6d5677d51b62df5